Compare JMM & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JMM | CCEL |
|---|---|---|
| Founded | 1988 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Managed Health Care |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.0M | 41.8M |
| IPO Year | N/A | 2022 |
| Metric | JMM | CCEL |
|---|---|---|
| Price | $5.50 | $4.87 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 8.1K | 7.6K |
| Earning Date | 01-01-0001 | 10-09-2026 |
| Dividend Yield | ★ 5.44% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.23 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $23.43 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $5.31 | $2.72 |
| 52 Week High | $6.36 | $5.45 |
| Indicator | JMM | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 44.44 | 51.48 |
| Support Level | $5.37 | $3.05 |
| Resistance Level | $5.89 | $5.45 |
| Average True Range (ATR) | 0.09 | 0.34 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 15.34 | 48.21 |
Nuveen Multi-Market Income Fund is a United States-based closed-end management investment company. The investment objective of the company is to provide high monthly income consistent with prudent risk to capital. The fund predominantly invests in debt securities, including, but not limited to, residential and commercial mortgage-backed securities, asset-backed securities, corporate debt obligations, convertible debt securities, U.S. government securities, and other such fixed income instruments. It may also invest in preferred stocks.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.